Duke University researchers report preclinical success with a liver-targeted siRNA therapy that silences a lysine-breakdown gene in glutaric aciduria type I (GA1), a rare inherited metabolic disorder. In mice, the treatment kept adult models alive and improved survival of treated neonatal models, even on high-protein diets.
The study was published in Science Translational Medicine.
This is a human health and biomedical research story with no link to feed, grain or oilseed supply, demand or prices.
Not enough comparable past events yet for a historical read.
Moves of each commodity's benchmark from the last close before the event. Historical reads pool past events of the same kind; they describe what happened, not what will. Not investment advice.